<DOC>
	<DOCNO>NCT02066025</DOCNO>
	<brief_summary>Octava two version , different intend use . OctavaPink qualitative vitro diagnostic test service , perform authorized clinical laboratory . The product use two follow indication : - Intend Use # 1 : OctavaPink indicate woman 18 year old , perform mammography determine negative breast cancer . Being moderately sensitive ( &gt; 55 % sensitivity ) test able detect 55 % mammography false negative . In addition , highly specific ( &gt; 95 % specificity ) supply additional evidence true mammography negative result reduce examinee anxiety misdiagnosed result high false negative mammography rate ( 10-30 % ) - Intend Use # 2 : OctavaPink indicate woman 18 year old , perform biopsy positive mammography biopsy result negative . Being moderately sensitive ( &gt; 55 % sensitivity ) test able detect 55 % biopsy false negative . In addition highly specific ( &gt; 95 % specificity ) supply additional evidence true biopsy negative result reduces examine anxiety misdiagnosed . OctavBlue qualitative vitro diagnostic test service , perform EventusDx authorized laboratory . Intend use OctavBlue following : â€¢ OctavBlue indicate woman 18 year old , perform mammography receive doubtful result . Being highly sensitive ( &gt; 95 % sensitivity ) test help reveal 95 % positive case ; moderately specific ( &gt; 55 % specificity ) - half negative case . The test intend use standalone diagnostic technique supply additional information physician help decide course diagnosis .</brief_summary>
	<brief_title>Blood Test Breast Cancer Associated Auto Antibodies - Improvement Octava Blood Test</brief_title>
	<detailed_description>The primary objective - To improve specification OctavaPink test OctavaBlue test . The current specification 1 . For OctavaPink - 95 % specificity 50 % sensitivity . 2 . For OctavaBlue - 50 % specificity 95 % sensitivity . The study consider successful option - 1 . If new antigen incorporate OctavaPink chip maintain specificity least 95 % increase sensitivity least 85 % . 2 . If new antigen incorporate OctavaBlue chip maintain sensitivity least 95 % increase specificity least 85 % .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Autoantibodies</mesh_term>
	<criteria>Female subject 18 year . Subjects follow mammography test . Subject pathological evaluation mammography BIRADS 3456 . Female Subjects less 18 year age Previous concurrent malignancy Autoimmune disorder diagnose subject Hematological malignancy Subjects active chemotherapy treatment chemotherapy past 6 month Steroid treatment past 3 month Subject undergoing immunosuppressive treatment Subject verify breast cancer invasive ductal invasive lobular verify biopsy/cytology</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>cancer associate auto antibody</keyword>
	<keyword>breast cancer blood test</keyword>
</DOC>